TD Cowen analyst Ken Cacciatore lowered the firm’s price target on Biohaven (BHVN) to $15 from $50 and keeps a Buy rating on the shares. The firm said the CRL for Vyglxia is highly disappointing, and they are unsure if it will ever make it to market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- 3 Best Stocks to Buy Now, 11/5/2025, According to Top Analysts
- FDA complete response letter cites issues in Biohaven Vyglxia NDA
- Biohaven Ltd.: Navigating Setbacks with Strategic Restructuring and Promising Pipeline
- Strategic Realignment and Pipeline Potential Drive Buy Rating for Biohaven Ltd.
- Video: What is dragging down Biohaven today